Johnson & Johnson
Change company
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
IE
US
US
US
US
US
US
IN
US
US
US
US
US
US
US
US
US
US
US
US
US
AU
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
JP
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
BM
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
Track Johnson & Johnson in real time with a live news feed covering Johnson & Johnson stock news, official press releases, company announcements, and an archive of historical Johnson & Johnson news. ...more
Loading news...
Loading more...
Sign in to download news snippet
Johnson and Johnson (JNJ) has reported encouraging early-stage results for its experimental prostate cancer drug, JNJ-6143, with 75% of evaluable patients experie
Read full articleNo data available for this time period.
Change the time range to see results.
Johnson and Johnson (JNJ) has reported encouraging early-stage results for its experimental prostate cancer drug, JNJ-6143, with 75% of evaluable patients experie
Read full article
If you are at or near retirement, the dividend that matters most is the one that keeps arriving and keeps growing through recessions, lawsuits and bear markets.
Read full article
Fifty-plus years of unbroken dividend raises sounds impressive until you ask whether the cash flow actually backs it up.
Read full article
SeaCrest Wealth Management LLC lessened its position in shares of Johnson and Johnson (NYSE: JNJ) by 50.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 9,992 shares of the company's stock after selling 10,130 shares during the quarter. SeaCrest Wealth Management LLC's
Read full article
Royal Fund Management LLC boosted its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 5.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,807 shares of the company's stock after purchasing an additional 2,076 shares during the period.
Read full article
NBT Bank N.A. bought a new position in shares of Johnson and Johnson (NYSE: JNJ) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 102,588 shares of the company's stock, valued at approximately $27,159,000. Johnson and Johnson accounts for 1.
8% of
Sepio Capital LP lessened its position in shares of Johnson and Johnson (NYSE: JNJ) by 12.4% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 18,091 shares of the company's stock after selling 2,551 shares during the period. Sepio Capital LP's holdings
Read full article
Root Financial Partners LLC boosted its stake in Johnson and Johnson (NYSE: JNJ) by 32.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 12,364 shares of the company's stock after buying an additional 3,063 shares during the quarter. Root Financial Partners LLC's
Read full article
During the quarter, we added 4 new positions and exited 14, bringing the number of positions in the Fund to 33. We initiated a position in Biogen Inc., a company that we believe is in the early stages of a transformation. We sold Madrigal Pharmaceuticals, Inc. to manage risk ahead of a competitor's clinical trial readout.
Dividend Kings have outperformed SPY YTD, rising 13.5% versus SPY's 12.32%, with a strong October rebound. Twenty-six Dividend Kings appear both potentially undervalued and offer long-term annualized expected returns of at least 10%. Dividend growth for the Kings in 2026 averages 4.
65%, with recent increases from GRC, NWN, and RPM.
No data available for this time period.
Change the time range to see results.